Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
153.70B
Market cap153.70B
Price-Earnings ratio
19.94
Price-Earnings ratio19.94
Dividend yield
6.36%
Dividend yield6.36%
Average volume
42.50M
Average volume42.50M
High today
$27.77
High today$27.77
Low today
$27.02
Low today$27.02
Open price
$27.71
Open price$27.71
Volume
29.12M
Volume29.12M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

Pfizer(PFE) stock is priced at $27.03, giving the company a market capitalization of 153.7B. It carries a P/E multiple of 19.94 and pays a dividend yield of 6.4%.

As of 2026-03-28, Pfizer(PFE) stock has fluctuated between $27.02 and $27.77. The current price stands at $27.03, placing the stock +0.0% above today's low and -2.7% off the high.

Pfizer(PFE) shares are trading with a volume of 29.12M, against a daily average of 42.5M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

PFE News

TipRanks 1h
Pfizer Stock Eyes Rebound as Vaccine Bets Heat Up

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Claim 30% Off TipRanks Premium Unlock hedge fund-lev...

TipRanks 1d
Option traders moderately bearish in Pfizer with shares down 0.67%

Option traders moderately bearish in Pfizer (PFE), with shares down 18c near $27.39. Options volume roughly in line with average with 52k contracts traded and c...

Simply Wall St 1d
Is Pfizer’s Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE?

Earlier this month, Pfizer and Valneva reported that their Phase 3 VALOR trial of the investigational 6‑valent Lyme disease vaccine showed more than 70% efficac...

Is Pfizer’s Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE?

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

24/7 Wall St. 2d
Income Investors Face a Hard Truth About Pfizer's Payout Safety

Income Investors Face a Hard Truth About Pfizer’s Payout Safety By Trey Thoelcke Published Mar 26, 7:55AM EDT Quick Read Pfizer (PFE) paid $9.771B in dividend...

Income Investors Face a Hard Truth About Pfizer's Payout Safety
Simply Wall St 2d
Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate

Pfizer and Valneva reported topline Phase 3 results for their experimental Lyme disease vaccine, showing over 70% efficacy but missing the primary statistical e...

Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate
Nasdaq 3d
Is Pfizer Stock a Buy After This Win?

Key Points Pfizer's recent phase 2 win was encouraging, but not yet a slam dunk. The company could make significant clinical and regulatory progress in the ne...

Is Pfizer Stock a Buy After This Win?
24/7 Wall St. 3d
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In By Joey Frenette Published Mar 25, 12:23PM EDT Quick Read Pfizer (P...

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In
Nasdaq 3d
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb BMY recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo. T...

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
TipRanks 3d
Notable open interest changes for March 25th

Tuesday’s total option volume of 56.5 million contracts resulted in net open interest growth of 7.38 million calls and 5.85 million puts. fuboTV (FUBO), NVIDIA...

Simply Wall St 4d
A Look At Pfizer Valuation As Shares Trade Near Recent Levels

Advertisement Pfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and sho...

A Look At Pfizer Valuation As Shares Trade Near Recent Levels

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.